COVID-19
Conditions
Keywords
Isoquercetin, Quercetin, Antiviral Agents
Brief summary
This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days following confirmation of a COVID-19 infection.
Detailed description
The primary purpose of this randomized study will be to evaluate the effect of Isoquercetin (IQC-950AN) treatment on disease progression (defined as ≥ 6 on the World Health Organization (WHO) clinical progression scale) when given to subjects with confirmed COVID-19 in addition to standard of care. The secondary purpose of this study is to evaluate the effect of Isoquercetin (IQC-950AN) treatment on the reduction of severe acute respiratory coronavirus 2 (SARS-CoV-2) viral titers in these subjects and their recovery. In addition, certain parameters which may help elucidate the mechanism of action (sLDLR, PCSK9, sACE2, D-dimers and CRP) will be followed. The safety of Isoquercetin (IQC-950AN) will be evaluated at each visit. Subjects will be randomized to receive treatment for 28 days and then will return 30 days following the discontinuation of treatment for a final safety visit. The results of this study will be used to design an adequately powered randomized controlled pivotal study to evaluate the efficacy and safety of Isoquercetin (IQC-950AN) in all or a subset of subjects with confirmed COVID-19.
Interventions
DRUGIsoquercetin (IQC-950AN)
Isoquercetin will be administered by mouth twice daily for 28 days
Sponsors
Pharmascience Inc.
SCiAN Services, Inc.
Quercis Pharma AG
Institut de Recherches Cliniques de Montreal
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must exhibit symptoms of COVID-19 disease at screening; 2. Patients must be 18 years of age or older, of either gender; 3. Patients must have a documented SARS-CoV-2 RNA-positive test virus within 3 days prior to randomization; 4. Patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for COVID-19 disease; 5. Patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the WHO clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. If female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. Patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. Patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. Patients must be able to swallow the study drug capsules
Exclusion criteria
1. Patients with a history of allergy or anaphylaxis to ingredients in Isoquercetin (IQC-950AN) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (G6PD) deficiency; 2. Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis; 3. Patients receiving an intensified dose regimen of low molecular weight heparin (LMWH) or unfractionated heparin (defined as doses of LMWH or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; 4. Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. Patients with moderate or severe thrombocytopenia (platelet count \<100 × 10⁹/L); 6. Patients who are breast-feeding an infant or child; 7. Patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. Any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. Any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease Progression | 28 days | Disease progression is defined as WHO Clinical Progression Scale ≥6, at any time between Day 1 and Day 28 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in viral load from baseline to end of treatment - Mean viral load | 28 days | Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) |
| Changes in viral load from baseline to end of treatment - Area under the viral load vs. time profiles | 28 days | Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) |
| Changes in viral load from baseline to end of treatment - Time profile of viral load | 28 days | Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) |
| Changes in viral load from baseline to end of treatment - Percentage of patients that are viral negative | 28 days | Defined as below the level of quantitation of the assay (qRT-PCR). Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) |
| Disease Recovery | 28 days | Disease recovery is defined as WHO Clinical Progression Scale score of ≤2 |
| Change in WHO Clinical Progression Scale score | 28 days | Change in score from baseline to day 28 |
| Incidence of all-cause mortality | 30 days | All-cause mortality calculated at Day 30 |
| Progression to supplementary oxygen requirement | 14 days | If the patient required supplementary oxygen during hospitalization |
| Changes in liver enzymes | 29 days | Changes in liver enzymes |
| Incidence of ICU admission | 14 days | If the patient was admitted to ICU |
| Time to hospital discharge | 29 days | Length of time in hospital prior to being discharged |
| Changes in serum C reactive protein levels (CRP) | 29 days | Changes in serum CRP levels |
| Changes in D-dimer levels | 29 days | Changes in D-dimer levels |
| Changes in soluble low-density lipoprotein receptor (sLDLR) expression and proprotein convertase subtilisin/kexin type 9 (PCSK9) and soluble angiotensin converting enzyme 2 (sACE2) levels | 29 days | Changes in sLDLR expression, and PCSK9 and sACE2 levels |
| Changes in LDL-cholesterol | 29 days | Changes in LDL-cholesterol |
| Changes in creatinine | 29 days | Changes in creatinine |
| Incidence of mechanical ventilation | 14 days | If the patient required mechanical ventilation during hospitalization |
Outcome results
None listed